探讨联合用药超选择动脉灌注治疗颅内恶性肿瘤的适应症、疗效及副作用，选择１２ 例颅内恶性肿瘤患者，将表阿霉素３０～４０ ｍ ｇ／ｍ ２，卡铂１５０～２００ ｍ ｇ／ｍ ２、ＶＰ１６ ６０～８０ ｍ ｇ／ｍ ２ 溶于生理盐水，采用超选择颈内动脉联合灌注化疗，治疗后４～６周复查强化ＣＴ，以评价早期疗效。定期复查血常规、肝肾功能，以判定化疗药物的毒副作用。本组病例近期ＣＲ３ 例、ＰＲ４ 例、ＮＣ４ 例、ＰＤ１ 例，肿瘤消失率２５％ ，有效率５８．１６％ 。化疗后瘤体积明显缩小（ｔ＝ ２．３９８，Ｐ＜ ０．０５），化疗后平均瘤体积缩小率为５３．６４％ 。肝酶异常升高者８３．３３％ ，血白细胞计数下降者达６７．６６％ ，但均在一月内恢复正常，表明所用的方法及化疗方案适用于无明显高颅压的颅内原发性和转移性恶性肿瘤，可以使瘤体积明显缩小甚至消失。但应注意药物的副作用，尤其是骨髓抑制。 To explore the indications, efficacy and side effects of combined use of superselective arterial infusion for the treatment of intracranial malignancies. 12 patients with intracranial malignancies were selected and 30 to 40 m g/m2 epirubicin and 150 to 200 m g carboplatin were selected. /m 2 , VP16 60 ~ 80 m g/m 2 dissolved in physiological saline, using superselective internal carotid artery infusion chemotherapy, 4 to 6 weeks after treatment review of enhanced CT, to evaluate the early efficacy. Periodic review of blood, liver and kidney function, to determine the toxic side effects of chemotherapy drugs. In this group of patients, there were recent CR3 cases, PR4 cases, NC4 cases, and PD1 cases. The tumor disappearance rate was 25%, and the effective rate was 58.16%. The tumor volume was significantly reduced after chemotherapy (t = 2.398, P < 0.05), and the average tumor volume reduction rate after chemotherapy was 53.64%. 83.33% of patients with abnormally elevated liver enzymes and 67.66% of patients with decreased blood white blood cell counts returned to normal within one month, suggesting that the methods and chemotherapy regimens used are suitable for intracranial primary disease without significant intracranial pressure. Sexual and metastatic malignancies can significantly reduce or even eliminate the tumor volume. However, attention should be paid to side effects of the drug, especially myelosuppression.